Biomarker Correlates of Clinical Outcomes from a Global phase 1b Study of JNJ-90014496, CD20/CD19 Bi-Specific Chimeric Antigen Receptor (CAR) T-cell Therapy for Patients with Large B-cell Lymphoma (LBCL)

Key Points

• Clinical outcomes correlate with specific biomarkers, indicating potential for more personalized therapy.
• The study highlights CD20 and CD19 as key biomarkers in predicting response to CAR T-cell therapy.
• Observational analysis across multiple centers evaluated efficacy in large B-cell lymphoma patients.
• Findings support the need for biomarker-driven approaches in addressing LBCL treatment strategies.